Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q3 FY25 results · Oct–Dec 2024
Natco Pharma reported revenue from operations of ₹474.80 crore (down 37.4% from Q3 FY24) and net profit of ₹132.40 crore (down 37.8% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 474.80 | 758.60 | −37.4% | 1,371.10 | −65.4% |
| Other income | 176.30 | 37.00 | +376.5% | 63.80 | +176.3% |
| Total income | 651.10 | 795.60 | −18.2% | 1,434.90 | −54.6% |
| Profit before tax | 163.70 | 256.30 | −36.1% | 818.20 | −80.0% |
| Net profit for the period | 132.40 | 212.70 | −37.8% | 676.50 | −80.4% |
| Attributable to shareholders of the company | 133.00 | 212.70 | −37.5% | 677.30 | −80.4% |
| EPS, basic (₹) | 7.43 | 11.88 | −37.5% | 37.81 | −80.3% |
| Net margin (%) | 27.9 | 28.0 | 49.3 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 407.60 | 625.30 | −34.8% | 1,292.60 | −68.5% |
| Other income | 168.00 | 29.50 | +469.5% | 51.40 | +226.8% |
| Total income | 575.60 | 654.80 | −12.1% | 1,344.00 | −57.2% |
| Profit before tax | 150.30 | 223.60 | −32.8% | 796.90 | −81.1% |
| Net profit for the period | 124.90 | 192.00 | −34.9% | 661.10 | −81.1% |
| EPS, basic (₹) | 6.97 | 10.72 | −35.0% | 36.91 | −81.1% |
| Net margin (%) | 30.6 | 30.7 | 51.1 |
Consolidated
- Filed with BSE
- 12 Feb 2025, 16:45 IST
- Board meeting
- 12 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Feb 2025, 16:45 IST
- Board meeting
- 12 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE